中文摘要：

目的探讨五岳抗甲丸辅助治疗Graves病（以下简称GD）的疗效及作用机制。方法将58例初诊GD患者随机分为观察组与对照组各29例，两组均口服他巴唑5-15mg或丙基硫氧嘧啶50-150mg，3次／d，观察组在此基础上加服五岳抗甲丸3-5g，3次／d。两组均连续用药3个月。观察两组治疗前后甲状腺体积及血清胰岛素样生长因子-I（IGF-I）水平变化，并行相关分析。结果两组治疗后甲状腺体积均明显缩小，血清IGF-I水平均下降，但观察组下降更明显（P〈0．01）。甲状腺体积与血清IGF-I水平呈正相关（r=0．57，P〈0．01）。结论五岳抗甲丸治疗GD效果确切，其机制可能为降低血清IGF-I的水平。

英文摘要：

Objective To study the effect of the Wuyue Kangjia Pill （WKP） in combination with medicine treatment on thyroid volumes and serum insulin-like growth factor-I （IGF-I） levels in patients with Graves disease （GD）. Methods 58 patients were divided into two groups： Group A was treated with methimazole （MT） or propyhhiouracil （PTU） alone and Group B was treated with MT or PTU combined with WKP. Thyroid volumes and serum IGF-I levels in patients were al- so observed in Group A and B before and after treatment. The correlation between thyroid volumes and serum IGF-I levels in patients was analyzed. Results The two parameters in Group A and Group B were decreased after treatment （P 〈 0.05 ）. They were decreased more in Group B than in Group A after treatment （all P 〈0.01 ）. There was a positive correlation between thyroid volumes and serum IGF-I levels in patients （ r = 0. 57, P 〈： 0.01 ）. Conclusions WKP in combination with western medicine treatment can improve goiters more effectively than only traditional western medicine by decreasing serum IGF-I levels of patients with GD.